Therapeuticdiscovery
Biosimilar Nivolumab
Originator: Opdivo (Bristol-Myers Squibb)
Biosimilar program of Nivolumab (Opdivo), an anti-PD-1 immune checkpoint inhibitor for multiple solid tumours.
Indications
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Head and neck squamous cell carcinoma
- Hodgkin lymphoma
Overview
Nivolumab (originator: Opdivo) is an anti-PD-1 monoclonal antibody used in immuno-oncology. IMGENEX India is in the early discovery phase of a biosimilar version.
Contact us today to learn more about this product. You can also email us at info@imgenexindia.com.